GAD65 References

GAD65 (B78) Human Monoclonal (Cat. #AB-N12), GAD65 (B96) Human Monoclonal (Cat. #AB-N13)

2 entries found for : gad65

Selective lesioning of nucleus incertus with corticotropin releasing factor-saporin conjugate.

Lee LC, Rajkumar R, Dawe GS (2014) Selective lesioning of nucleus incertus with corticotropin releasing factor-saporin conjugate. Brain Res 1543:179-190. doi: 10.1016/j.brainres.2013.11.021

Summary: In this work the authors used CRF-SAP (Cat. #IT-13) to eliminate CRF1 receptor-expressing cells from the nucleus incertus (NI). Rats received bilateral CRF-SAP injections of 21.5 to 86 ng into the NI. Blank-SAP (Cat. #IT-21) was used as a control. Lesioned animals displayed a significant loss of CRF1 receptor-expressing cells, along with a decrease in relaxin-3 and GAD65 expression.

Related Products: CRF-SAP (Cat. #IT-13), Blank-SAP (Cat. #IT-21)

Read the featured article in Targeting Trends.

Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves’ disease: a comparison with those present in type1 diabetes.

Tremble J, Morgenthaler NG, Vlug A, Powers AC, Christie MR, Scherbaum WA, Banga JP (1997) Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type1 diabetes. J Clin Endocrinol Metab 82(8):2664-2670. doi: 10.1210/jcem.82.8.4171

Related Products: GAD65 (B78) Human Monoclonal (Cat. #AB-N12), GAD65 (B96) Human Monoclonal (Cat. #AB-N13)